NASDAQ:BFRI

Biofrontera (BFRI) Stock Price, News & Analysis

Biofrontera logo
$0.57 -0.03 (-4.97%)
Closing price 04:00 PM Eastern
Extended Trading
$0.62 +0.05 (+8.95%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Biofrontera Stock (NASDAQ:BFRI)

Advanced

Key Stats

Today's Range
$0.57
▼
$0.63
50-Day Range
$0.57
▼
$1.55
52-Week Range
$0.54
▼
$1.66
Volume
113,372 shs
Average Volume
201,130 shs
Market Capitalization
$8.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Reduce

Company Overview

Biofrontera Inc. is a biopharmaceutical company focused on dermatology and the commercial development of prescription products for treating skin conditions. Its business is primarily centered on the U.S. market.

The company’s main product is Ameluz, a topical gel containing aminolevulinic acid hydrochloride. It is used with Biofrontera’s BF-RhodoLED light device in photodynamic therapy to treat certain actinic keratoses, precancerous lesions that can develop on sun-damaged skin.

Biofrontera’s products combine a topical treatment with a specialized light source, which activates the treatment during a clinical procedure. The company was formerly associated with German pharmaceutical company Biofrontera AG and became an independent U.S. public company in 2023.

AI Generated. May Contain Errors.

Biofrontera Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
16th Percentile Overall Score

BFRI MarketRank™: 
0.8071379547 of 5 stars

Biofrontera scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Biofrontera has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    Biofrontera has only been the subject of 1 research reports in the past 90 days.

  • Read more about Biofrontera's stock forecast and price target.
    • Percentage of Shares Shorted

      1.39% of the float of Biofrontera has been sold short.
    • Short Interest Ratio / Days to Cover

      Biofrontera has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
    • Change versus previous month

      Short interest in Biofrontera has recently increased by 83.84%, indicating that investor sentiment is decreasing significantly.
    • Dividend Yield

      Biofrontera does not currently pay a dividend.

    • Dividend Growth

      Biofrontera does not have a long track record of dividend growth.

    • News Sentiment

      Biofrontera has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.
    • News Coverage This Week

      MarketBeat has tracked 10 news articles for Biofrontera this week, compared to 2 articles on an average week.
    • Search Interest

      Only 1 people have searched for BFRI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
    • Insider Buying vs. Insider Selling

      In the past three months, Biofrontera insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      8.10% of the stock of Biofrontera is held by insiders.

    • Percentage Held by Institutions

      10.08% of the stock of Biofrontera is held by institutions.

    • Read more about Biofrontera's insider trading history.
    Receive BFRI Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter.

    SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

    BFRI Stock News Headlines

    Biofrontera: 3 Key Takeaways for Long-Term Investors
    Biofrontera (NASDAQ:BFRI) Issues Quarterly Earnings Results
    $0. Later: $29.97.
    Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.tc pixel
    Biofrontera Inc. (BFRI) Stock Falls on Q3 2026 Earnings
    See More Headlines

    BFRI Stock Analysis - Frequently Asked Questions

    Biofrontera's stock was trading at $0.57 on January 1st, 2026. Since then, BFRI stock has increased by 0.0% and is now trading at $0.57.

    Biofrontera Inc. (NASDAQ:BFRI) released its quarterly earnings results on Friday, November, 13th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.31. The business earned $9.07 million during the quarter, compared to analysts' expectations of $8.50 million. Biofrontera had a negative trailing twelve-month return on equity of 131.54% and a negative net margin of 12.72%.
    Read the conference call transcript
    .

    Biofrontera's stock reverse split on Wednesday, July 5th 2023.The 1-20 reverse split was announced on Wednesday, July 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

    Biofrontera (BFRI) raised $19 million in an initial public offering on Friday, October 29th 2021. The company issued 3,100,000 shares at a price of $5.00-$7.00 per share. Roth Capital Partners and The Benchmark Company served as the underwriters for the IPO.

    Biofrontera's top institutional investors include AIGH Capital Management LLC (10.08%) and Virtu Financial LLC (0.28%).

    Shares of BFRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Biofrontera investors own include Lucid Group (LCID), Longeveron (LGVN), Tesla (TSLA), AMC Entertainment (AMC), Ford Motor (F), iSpecimen (ISPC) and Pasithea Therapeutics (KTTA).

    Company Calendar

    Last Earnings
    11/13/2026
    Today
    11/19/2026
    Fiscal Year End
    12/31/2026

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Industry
    Pharmaceuticals
    Sub-Industry
    Pharmaceuticals
    Current Symbol
    NASDAQ:BFRI
    CIK
    1858685
    Fax
    N/A
    Employees
    94
    Year Founded
    2012

    Profitability

    EPS (Trailing Twelve Months)
    ($0.25)
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$10.54 million
    Net Margins
    -12.72%
    Pretax Margin
    -12.67%
    Return on Equity
    -131.54%
    Return on Assets
    -29.61%

    Debt

    Debt-to-Equity Ratio
    0.78
    Current Ratio
    0.78
    Quick Ratio
    1.08

    Sales & Book Value

    Annual Sales
    $41.71 million
    Price / Sales
    0.20
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    ($0.02) per share
    Price / Book
    -28.50

    Miscellaneous

    Outstanding Shares
    14,850,000
    Free Float
    13,649,000
    Market Cap
    $8.46 million
    Optionable
    No Data
    Beta
    0.88

    Social Links

    7 Best Space Stocks to Own in 2026 Cover

    The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

    Get This Free Report

    This page (NASDAQ:BFRI) was last updated on 11/19/2026 by MarketBeat.com Staff.
    From Our Partners